Metabolism and pharmacokinetics of 1-(2'-hydroxyethyl)- and 1-(3'-hydroxypropyl)-2-ethyl-3-hydroxypyridin-4-ones in the rat

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 21, Issue 1, 1996, Pages 33-41

  Singh, S ^a   Choudhury, R ^a   Epemolu, R O ^a   Hider, R C ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

3 hydroxypyridin 4 one; Chelator; Iron; Metabolism; Pharmacokinetics

Indexed keywords

2 ETHYL 3 HYDROXY 1 (2 HYDROXYETHYL) 4 PYRIDINONE; 3 HYDROXY 4 PYRIDONE DERIVATIVE; CHELATING AGENT; CP 106; CP 110; DRUG METABOLITE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG RETENTION; DRUG URINE LEVEL; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CLEARANCE; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT;

EID: 0030056173     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03190276     Document Type: Article

References (17)

1. Singh S. Hider R.C. (1994) : Therapeutic iron-chelating agents. In: Rice-Evans C.A., Burdon R.H. (Eds). Free Radical Damage and its Control. Amsterdam, Elsevier, pp. 189-213.
2. Hider R.C., Singh S., Porter J.B., Huehns E.R. (1990) : The development of hydroxypyndin-4-ones as orally active iron chelators Ann NY Acad. Sci., 612, 327-338.
3. Pippard M J., Letsky E.A., Callender S.T., Weatherall D.J. (1978) Prevention of iron loading in transfusion-dependent thalassaemia Lancet, i. 1178-1180.
4. Propper R D., Cooper B., Rufo R., et al. (1977) : Continuous subcutaneous administration of desferrioxamine in thalassaemia major. N Engl. J. Med., 297. 418-423.
5. Lee P. Mohammed N., Marshall L., et al. (1993) : Intravenous infusion pharmacokinetics of desferrioxamine in thalassaemic patients Drug Metab Dispos., 21, 640-644.
6. Hider R C., Porter J.B., Singh S (1994) : The design of therapeutically useful iron chelators. In: Bergeron R.J., Brittenham G.M. (Eds) The Development of Iron Chelators for Clinical Use. Florida, CRC Press, pp. 353-371.
7. Porter J B. Huehns E.R., Hider R.C. (1989) : The development of iron chelating drugs. Ballieres Clin. Haematol., 2, 257-292.
8. Kontoghiorghes G.J., Aldouri M.A., Hoffbrand A V., et al. (1987) : Effective chelation of iron in β-thalassaemia with the oral iron chelator 1,2-dimethyl-3-hydroxypyridin-4-one. BMJ, 295, 1509-1512.
9. Oliveri N.F., Koren G., Hermann C., et al. (1990) : Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients, Lancet, 336, 1275.
10. Agarwal M.B., Gupta S.S., Visvanathan C., et al. (1992) : Longterm assessment of efficacy and safety of L1, an oral iron chelator in transfusion dependent thalassaemia: Indian trial. Br. J. Haematol., 82, 460-466.
11. Tondury P., Kontoghiorghes G. J., Ridolfi-Luthy A , et al. (1990) : L1 (1,2-dimethyl-3-hydroxypyridin-4-one) for oral iron chelation in patients with β-thalassaemia major. Br. J. Haematol., 76, 550.
12. Porter J B., Abeysinghe R.D., Barra C., et al. (1991) : Oral efficacy and metabolism of 1,2-diethyl-3-hydroxypyridin-4-one in thalassaemia major (Abstract). Blood, 78, 2071.
13. Singh S., Epemolu R.O., Dobbin P.S., et al. (1992) : Urinary metabolic profiles in man and rat of 1,2-dimethyl- and 1,2-diethyl substituted 3-hydroxypyridin-4-ones. Drug Metab. Dispos., 20, 25.
14. Singh S., Epemolu R.O., Ackerman R., Porter J.B., Hider R.C. (1992) : Development of 3-hydroxypyridin-4-ones which do not undergo extensive phase II metabolism, 3rd NIH-Sponsored Symposium on The Development of Iron Chelators for Clinical Use, Gainsville, FL, Abstract # 52.
15. Singh S (1994) : Therapeutically useful iron chelators, Chem. Ind., 452-455.
16. Dobbin P.S., Hider R.C., Hall A.D., et al. (1993) : Synthesis, physiochemical properties and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4-(1H)-pyridinones: orally active iron chelators with clinical potential. J. Med. Chem., 36, 2448-2458.
17. Jin Y, Singh S., Epemolu R.O., et al. (1993) : CP102; a potent orally active iron chelator. Proceedings of the European Iron Club Meeting, London